ACADIA PHARMACEUTICALS INC — Director's Dealing 2014

May 2, 2014

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ACADIA PHARMACEUTICALS INC (ACAD)
CIK: 0001070494
Period of Report: 2014-05-01

Reporting Person: Rasmussen Torsten (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2014-05-01	Common Stock	M	6500	$8.85	Acquired	15000	Indirect
2014-05-01	Common Stock	M	2542	$8.85	Acquired	17542	Indirect
2014-05-01	Common Stock	M	8500	$11	Acquired	26042	Indirect
2014-05-01	Common Stock	M	10000	$9.04	Acquired	36042	Indirect
2014-05-01	Common Stock	M	5315	$15.02	Acquired	41357	Indirect
2014-05-01	Common Stock	S	32857	$20.0333	Disposed	8500	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2014-05-01	Stock option (right to buy)	$8.85	M	6500	Disposed	2015-06-09	Common Stock (6500)	Indirect
2014-05-01	Stock option (right to buy)	$8.85	M	2542	Disposed	2015-06-09	Common Stock (2542)	Indirect
2014-05-01	Stock option (right to buy)	$11	M	8500	Disposed	2015-09-08	Common Stock (8500)	Indirect
2014-05-01	Stock option (right to buy)	$9.04	M	10000	Disposed	2016-06-12	Common Stock (10000)	Indirect
2014-05-01	Stock option (right to buy)	$15.02	M	5315	Disposed	2017-06-14	Common Stock (5315)	Indirect

Footnotes

F1: Shares and options are held by Morgan Management Aps, a Danish corporation in which Mr. Rasmussen has a controlling interest.

F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in June 2013.

F3: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $19.55 to $20.32 per share, inclusive. The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range.

F4: 25% of the shares subject to the stock option vested and became exercisable at the end of each 3-month period following the date of grant of June 10, 2005.

F5: 25% of the shares subject to the stock option vested and became exercisable at the end of each 3-month period following the date of grant of September 9, 2005.

F6: 25% of the shares subject to the stock option vested and became exercisable at the end of each 3-month period following the date of grant of June 13, 2006.

F7: 25% of the shares subject to the stock option vested and became exercisable at the end of each 3-month period following the date of grant of June 15,2007.